Excess body weight—including overweight and obesity—is a significant risk factor for cancer. Research from the American Cancer Society estimates that it contributes to approximately 5 percent of ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...